The internal operational challenge surrounding OTC derivatives remains an area that individual firms have to take responsibility for. In early 2008 we were obsessed about volume, bottlenecks and efficiency, in 2009 we are facing a slightly different operational challenge; that of counterparty risk and exposure management and underlying principles o...